... 33(4):445-8 Early BreastCancer Trialists’ Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomized trials Lancet 1998, 351:1451-1467 Cuzick J, Powles T, Veronesi U, Forbes ... for Research on Cancer, Lyon, France 1996, 66:253-365 11 Swerdlow AJ, Jones ME: Tamoxifen treatment forbreastcancerand risk of endometrial cancer: a case-control study J Natl Cancer Inst 2005, ... toxicity and feasibility of tamoxifen for prevention of breastcancer Br J Cancer 1989, 60(1):126-31 Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM: Endometrial cancer...
... Darby S, Early BreastCancer Trialists’ Collaborative Group (EBCTCG): Effects of radiotherapy and of differences in the extent of surgery for early breastcancer on local recurrence and 15-year ... START Trialists’ Group: The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial Lancet 2008, 9:331-41 ... START Trialists’ Group: The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial Lancet 2008, 371:1098-17...
... withdrawn and the primary tumor alone is treated to 79,2 Gy V20 right and left lung and V25 both lungs is 49%, 22% and 26%, respectively V50 for the heart is 2% Peripheral tumor located lateral and ... proposed this method for head and neck, breastand craniospinal treatments With the availability of independently moving jaws asymmetric collimators were used to split the beam for head and neck patients ... tinely for lung cancer patients in all stages During the past years, this technique has continuously been evolved with regard to optimizing the procedures for quality assurance and raising conformity...
... greater cytotoxicity after longer treatments (72 hours) Furthermore, it was also demonstrated that its cytotoxic effect differed between breast normal (MCF-10A) andbreast carcinoma (4T1 and MCF-7) ... investigator and takes primary responsibility for the paper MLBC, ZGML, ARS* and SNB participated in the design of the study and SNB co-ordinated the research; MLBC, ESN, RCAP, RGSO and LHML performed ... of a- and b-carboxyl carbon atoms in the complex (195.3 and 192.8 ppm, respectively) appear shifted in comparison with those with free ligands (179 and 176.5 ppm, respectively) The shift and split...
... BRCA1 and BRCA2 increase individual risks forbreastcancer 60-85% and may be identified in 5-10% of all breastcancer cases.28 Personal history of noninvasive breastcancer or previous abnormal breast ... Tripathy D Targeted therapies in breastcancerBreast 2005;11(Suppl 1):S30-S35 Smith RA, Saslow D, Sawyer KA, et al American Cancer Society guidelines forbreastcancer screening: Update 2003 CA: Cancer ... interventions, outcomes, and harms of the screening process (Figure 1) The target population includes women without preexisting breastcancerand not considered at high risk forbreastcancerbased on extensive...
... you would like further information: • the National BreastCancer Coalition (www.stopbreastcancer.org), whose members are mainly women with breast cancer, and • the Center for Medical Consumers (www.medicalconsumers.org) ... cell changes and cancers, all of them are treated Therefore, screening results in treatment of many women for a cancer disease they not have, and that they will not get Based on the randomised trials, ... disease andcancer It therefore no longer seems reasonable to attend forbreastcancer screening In fact, by avoiding going to screening, a woman will lower her risk of getting a breast cancer...
... docetaxel-loaded nanoparticles based on poly(lactideco-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies ... characterized for particle size, zeta potential, EE%, drug release kinetics, morphology, crystallinity, and cytotoxicity on the SUM 225 breastcancer cell line by dynamic light scattering, high performance ... precursor compound, and then isolated [2] Doc is a highly potent, cytotoxic, and antimitotic agent used in the treatment of various types of cancers, including metastatic breast, ovarian, prostate,...
... 10.380, 8.726, and 5.945 lg/mL for TaxotereÒ to 7.388, 3.643, and 1.244 lg/mL for PCL NP formulation and to 1.019, 0.384, and 0.196 lg/mL for PCL/Pluronic F68 NP formulation after 24, 48, and 72 h ... 49.16% (i.e a 11.42% increase in cytotoxicity, p [ 0.05) for PCL NP formulation and 36.63% (i.e a 38.88% increase in cytotoxicity, p \ 0.05) for PCL/Pluronic F68 NP formulation Similarly, it can ... release was only 13.57, 20.61, and 27.94% for PCL nanoparticles and 22.40, 31.09, and 37.44% for PCL/Pluronic F68 nanoparticles after 1, 2, and days, respectively, and the release started from...
... enough for therapeutic selection but knowledge of both genotype and phenotype is required Furthermore, Chin et al [1] provide lists of copy number alterations and potential cancer genes in breast cancers ... including self-renewal and tumorigenicity in breastcancer cells [14] and also invasion and metastasis [15,16] They are thought to be important in oncogenesis (see [17,18] for reviews) Journal ... subtypes [2] and of variations in genome instability and heterogeneity of estrogen receptor (ER)-negative tumors [1] (arrows) contribute to the understanding and classification of breast cancers Blenkiron...
... BK: Seroma formation following breastcancer surgery Breast J 2003, 5:385-8 Woodworth PA, McBoyle MF, Helmer SD, Beamer RL: Seroma formation after breastcancer surgery: incidence and predicting ... following breastcancer surgeries: seromas following breastcancer surgeries Breast J 2007, 13:588-92 Burak WE Jr, Goodman PS, Young DC, Farrar WB: Seroma formation following axillary dissection forbreast ... since October 2007 and is designed for open procedures It has been used for dissection in surgery of the liver, gallbladder, thyroid andbreast [13-18] It has been used in other lymphatic dissections...
... of JFR and KLC AA collected data, performed analysis, drafted, revised and finalised the manuscript KLC and JFR revised and approved of the contents of the manuscript All authors read and approved ... Dodwell DJ, Anderson H, Redford J: Response after withdrawal of tamoxifen and progestogens in advanced breastcancer Annals Of Oncology: Official Journal Of The European Society For Medical Oncology/ ... Schiff R: Crosstalk between Estrogen Receptor and Growth Factor Receptor Pathways as a Cause for Endocrine Therapy Resistance in BreastCancer Clinical Cancer Research 2005, 112:865s-870s Legault-Poisson...
... of the female breast A long-term follow-up study Cancer 1985, 55:2698-2708 Dupont WD, Page DL: Risk factors forbreastcancer in women with proliferative breast disease New England Journal of ... sequence alignment and drafted and described the manuscript AL carried out the Pathologic diagnosis BJS and SSJ conceived of the study, and participated in its design and coordination and helped to ... American College of Radiology Breast Imaging Reporting and Data System lexicon and the final assessment categories All lesions were evaluated for size on imaging and presence of microcalcification...
... relationship forbreastcancer was derivedbased on the analysis of breastcancer induction after Hodgkin’s disease, a cancer risk model developed for high doses including fractionation based on ... of model parameters for a dose-response relationship forbreastcancer covering dose levels relevant for radiotherapy In addition a model for the age dependence of breastcancer risk was verified ... were treated for Hodgkin’s disease between 1965 and 1994 The mean and median age at diagnosis was 22 years Point dose reconstruction for the breastcancer was possible for 102 cases and 257 controls...
... these novel therapies to current treatment standards and to continue to search for newer agents that are under investigation for use in breastcancer The role of most of these biologic and targeted ... currently approved for the treatment of both colorectal cancerand head and neck cancer Its use in breastcancer has been evaluated in a phase II study of weekly irinotecan and carboplatinum with ... necessary forcancer growth, invasion and metastasis Several therapeutic agents have been developed which target this pathway and have already been incorporated into standard treatment regimens for...
... to patients Patient-held mini-records of preventive services Performance targets for mammographyc Performance targets for clinical breast exams 33 14 20 26 10 52 44 34 17 0.6 16 10 0.01 0.05 0.02 ... routine use of performance targets for mammography, compared to 8% of the control physicians (p = 0.009) Fifty percent of the physicians had performance targets for clinical breast examinations; ... Oncology, March, 2002 References American Cancer Society: BreastCancer Facts and Figures 2005–2006 Atlanta: American Cancer Society, Inc Centers for Disease Control and Prevention, 2003 National Health...
... to patients Patient-held mini-records of preventive services Performance targets for mammographyc Performance targets for clinical breast exams 33 14 20 26 10 52 44 34 17 0.6 16 10 0.01 0.05 0.02 ... routine use of performance targets for mammography, compared to 8% of the control physicians (p = 0.009) Fifty percent of the physicians had performance targets for clinical breast examinations; ... Oncology, March, 2002 References American Cancer Society: BreastCancer Facts and Figures 2005–2006 Atlanta: American Cancer Society, Inc Centers for Disease Control and Prevention, 2003 National Health...
... REPORT Open Access Conformational alterations in the CD4 binding cavity of HIV-1 gp120 influencing gp120-CD4 interactions and fusogenicity of HIV-1 envelopes derived from brain andother tissues Lachlan ... function, by characterizing, for the first time, the structure-function relationships of a larger panel of Envs derived from brain andother tissues (n = 81) Production and characterization of a ... established and characterized a new panel of Envs (n = 81) derived from autopsy brain andother tissues of subjects who died from AIDS Production of three-dimensional gp120 models and characterization...
... JNK/cJUN signalling and its role in cancer 37 1.5.2 STAT3 signalling and its role in cancer 39 1.6 Breastcancer 42 1.6.1 Tumour microenvironment andbreastcancer progression ... thank you for being so understanding, supportive and caring during the last year of my study Thanks for sharing my joy, sorrow and hardship Thank you for being there and looking out for me all ... 77,78, pancreatic cancer 79; and with bone metastasis in breast 80,81 and prostate cancers 82 Similarly, α6β4 expression in breastcancer could be correlated to increase in tumour size and reduced...